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Neurodynamic treatment improves leg pain, back pain, function and global
perceived effect at 4 weeks in patients with chronic nerve-related leg painWe are concerned about the reporting of the trial ‘Neurody-
namic treatment did not improve pain and disability at two weeks
in patients with chronic nerve-related leg pain’.1 [1_TD$DIFF] There is a
tendency to simplify the findings of clinical trials into binary
conclusions (either positive or negative) based on the analysis of
the primary outcomes.2 Often, a more nuanced interpretation is
required by thoroughly examining the totality of the evidence, not
just the primary outcomes.2 In our opinion, this nuance is lacking
in the study by Ferreira et al.1 If we follow their conclusions, we
risk discarding valuable interventions, as is evident from their
own1 and other studies.3
In line with their protocol paper, the authors prioritised
immediate treatment effects (ie, immediately after a 2-week
intervention) over intermediate follow-up (4 weeks after baseline,
or 2 weeks after the last treatment session). This is unconventional.
Intermediate and long-term effects should have priority over
immediate effects.4 The choice of primary outcomes was, in our
view, suboptimal and unfortunate, and greatly impacted the
study’s conclusions. A different and probably more logical
selection of primary outcomes (eg, leg or back pain, function or
global perceived effect at 4 weeks) would have led to the opposite
conclusion. This favourable conclusion would have been consistent
with the findings from a clinical trial on neurodynamics for nerve-
related neck-arm pain,3 on which the design of this study was
modelled. Although our somewhat provocative title might suggest
otherwise, we obviously do not advocate selective reporting of
planned secondary outcomes. More nuance is and was required.
The study aimed to compare, at two timepoints, the effect of
neurodynamic treatment versus wait-and-see on leg pain,
disability, back pain, function, global perceived effect, and the
proportion of participants whose leg pain centralised. The title,
conclusions and choice of primary outcomes should better reflect
all aims of the study. Leg pain and disability were primary
outcomes immediately after treatment, but were not considered
important enough to be primary outcomes at 4 weeks. We fail to
see the rationale behind this. In a trial where rapid change would
be unexpected, 4-week outcomes seem more important because:
only four treatment sessions were prescribed in patients with
a chronic condition, and neuropathic pain and nerve root1836-9553/ 2016 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/4.0/).compromise, which are likely indicators of a less favourable
prognosis for neurodynamic5,6 and other interventions, were
prevalent (26/60 and 33/60 patients, respectively). There was indeed
a significantly larger improvement for leg pain, back pain, function
and global perceived effect in favour of neurodynamic treatment at
4 weeks (as well as function and global perceived effect immediately
after treatment). We believe that these are valuable outcomes.
Another concern is the choice of Oswestry Disability Index as a
primary outcome over the Patient Specific Functional Scale, which
was secondary. Maughan and Lewis7 revealed that the Patient-
Specific Functional Scale was more responsive than the Oswestry
Disability Index and Roland-Morris Disability Index in people with
back pain. In the study by Ferreira et al,1 the Patient-Specific
Functional Scale results favoured neurodynamic treatment at both
timepoints.
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http://dx.doi.org/10.1016/j.jphys.2016.09.001[1_TD$DIFF] rial [2_TD$DIFF]of [3_TD$DIFF]neurodynamic [4_TD$DIFF]treatment [5_TD$DIFF]was [6_TD$DIFF]reported accurately and appropriatelyWe would like to thank the editor-in-chief of Journal of
Physiotherapy for the opportunity to address Hall and colleagues’
concerns about our randomised trial of neurodynamic treatment
for chronic nerve-related leg pain.1 Hall and colleagues stated that:
the reporting of our results, emphasising the findings of the
primary outcomes, has led to a binary and oversimplified
conclusion that neurodynamic treatment ‘does not work[8_TD$DIFF]’ despitethe findings of some secondary outcomes; the choice of leg pain
and disability as primary outcomes only at 2 weeks, but not at
4 weeks also, was illogical; the selection of the intermediate
follow-up (4 weeks) as the primary outcome would have been
more adequate than the short-term follow-up that we chose; and
we should have considered using the Patient-Specific Functional
Scale (PSFS) rather than the Oswestry Disability Index (ODI) as one.V. This is an open access article under the CC BY-NC-ND license (http://
